TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th thro ...

TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), held in Vienna, Austria from Decem ...

– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., comment ...

TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be avai ...

Core Viewpoint - Picard Medical, Inc. has stated that it is not aware of any undisclosed material changes in its operations or financial condition that would explain the recent volatility in its stock price [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [3] - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [3] Strategic Focus - The company remains committed to executing its strategic and operational priorities while ensuring compliance with all disclosure obligations under applicable securities laws [2]

Core Viewpoint - Picard Medical, Inc. reported significant financial growth driven by strong sales of its SynCardia total artificial heart, achieving over 200% revenue growth year-over-year and successfully completing an IPO that raised $19.5 million to support future developments [2][3][7]. Financial Performance - **Second Quarter 2025 Results**: Revenue increased by 207% to $2.13 million from $0.69 million in Q2 2024, primarily due to higher U.S. product sales. Gross loss improved by 67% to $0.13 million, while operating loss decreased by 8% to $3.52 million. Net loss was $6.72 million, up from $4.06 million in the prior year, influenced by higher non-cash debt discount and derivative losses [3][5]. - **Year-to-Date 2025 Results**: For the first half of 2025, revenue rose by 3% to $2.74 million compared to $2.67 million in the same period of 2024. Gross loss was $0.49 million, contrasting with a gross profit of $0.43 million in the first half of 2024. Operating loss widened by 19% to $6.77 million, and net loss increased to $12.29 million from $6.01 million in the prior year, again due to higher non-cash debt discount and derivative losses [4][5]. Company Outlook - Following the successful IPO, the company anticipates funding operations into 2026 and aims to enhance the adoption of its total artificial heart while advancing its next-generation fully implantable heart platform, the Emperor [6]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for its SynCardia Total Artificial Heart, the only commercially available total artificial heart technology in the U.S. and Canada, with over 2,100 implants performed globally [7][8].

Core Insights - Picard Medical, Inc. has strengthened its Board of Directors by appointing Sam Van and George Ye, who bring extensive expertise in capital markets and medical technology [1][2][3] Group 1: Board Appointments - Sam Van has a strong background in financial and capital markets, having held senior positions at Freedom U.S. Markets and the New York Stock Exchange, where he was involved in over 60 new listings [2][3] - George Ye has extensive experience in the medical device industry, having served in senior roles at Edwards Lifesciences and previously at Abbott Laboratories and Johnson & Johnson [3] Group 2: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, which is known for its SynCardia Total Artificial Heart, the only commercially available total artificial heart technology in the U.S. and Canada [4] - The SynCardia Total Artificial Heart has been implanted over 2,100 times across 27 countries, making it the most widely used artificial heart globally [4]

Core Points - Picard Medical, Inc. successfully closed its initial public offering (IPO) of 4,250,000 shares at a price of $4.00 per share, generating gross proceeds of $17 million before deductions [1] - The company has granted underwriters an option to purchase an additional 637,500 shares to cover over-allotments within 30 days of the offering [1] - The shares began trading on the NYSE American under the ticker symbol "PMI" on August 29, 2025 [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized as the leader in total artificial heart technology for patients with end-stage heart failure [5] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart approved by both the FDA and Health Canada, with over 2,100 implants performed across 27 countries [5] - The STAH is noted for being the most widely used and extensively studied artificial heart globally [5]

Core Viewpoint - Picard Medical, Inc. has announced the pricing of its initial public offering (IPO), aiming to raise $17 million through the sale of 4,250,000 shares at $4.00 per share, with trading expected to commence on August 29, 2025 under the ticker symbol "PMI" [1][3]. Group 1: Offering Details - The IPO consists of 4,250,000 shares priced at $4.00 each, totaling gross proceeds of $17 million before expenses [1]. - Underwriters have an option to purchase an additional 637,500 shares within 30 days to cover over-allotments [1]. - The offering is being conducted on a firm commitment basis, with WestPark Capital, Inc. as the Lead Manager and Sole Bookrunner [2]. Group 2: Use of Proceeds - Proceeds from the IPO will support market expansion in China through a joint venture, fund research and development for new products, and enhance sales and marketing capabilities [3]. - The funds will also be used to repay debt and cover general operational expenses and working capital [3]. Group 3: Company Background - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which manufactures the SynCardia Total Artificial Heart (STAH), the only FDA and Health Canada approved total artificial heart [6]. - The STAH is the most widely used artificial heart globally, with over 2,100 implants performed in 27 countries [6].